Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights

Gulab, Asma; Torres, Ricardo; Pelayo, Jerald; Lo, Kevin Bryan; Shahzad, Anum; Pradhan, Swetalina; Rangaswami, Janani

doi:10.1080/14779072.2021.1941873

Cited by 7 publications

(3 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, the change in haematocrit could have simply been masked in this single case, and the absence of an increase in haematocrit levels in our patient does not rule out SGLT‐2‐inhibitor‐dependent effects on plasma volume or haematopoiesis. Of interest, we did observe a 35% decrease in the levels of uric acid, suggesting that there might be an SGLT‐2‐inhibitor‐dependent improvement of the cardio‐renal axis 17 …”

Section: Discussionmentioning

confidence: 71%

“…Of interest, we did observe a 35% decrease in the levels of uric acid, suggesting that there might be an SGLT-2-inhibitor-dependent improvement of the cardio-renal axis. 17 Looking beyond pharmacological options for advanced sRV failure, we enter the domain of heart transplantation and ventricular assist device (VAD) therapy. 18,19 Although our patient is young without extracardiac comorbidities and is currently being screened for cardiac transplantation eligibility, donor hearts remain scarce and Dutch data report a high waiting list mortality (15% before a suitable donor becomes available) with a median waiting time of 2.6 years and only 50% of the eligible patients being transplanted in the period 2013-17.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure

et al. 2022

View full text Add to dashboard Cite

In congenitally corrected transposition of the great arteries, the morphological right ventricle supports the systemic circulation. This chronic exposure to pressure overload ultimately leads to systemic right ventricular (sRV) dysfunction and heart failure. Pharmacological options for the treatment of sRV failure are poorly defined and no solid recommendations are made in the most recent guidelines. Sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors are a new class of antihyperglycaemic drugs that have been demonstrated to significantly reduce the risk of worsening heart failure and death from cardiovascular causes in patients with chronic heart failure with reduced left ventricular ejection fraction, yet no data are available in sRV patients. We report on the treatment and clinical follow‐up of a patient with advanced heart failure and poor sRV function in the context of congenitally corrected transposition of the great arteries, who did not tolerate sacubitril/valsartan and had a high burden of heart‐failure‐related hospitalizations. Treatment with dapagliflozin was well tolerated and resulted in (small) subjective and objective functional and echocardiographic improvement and a reduction in heart‐failure‐related hospitalizations.

show abstract

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure

et al. 2022

View full text Add to dashboard Cite

show abstract

“…When serum uric acid (SUA) levels exceed urate solubility, i.e., at approximately 6.8 mg/dL, monosodium urate crystal will form and be deposited in tissues. Increased SUA was reported to serve as a pro-oxidant agent and promote oxidative stress ( 3 ). Hyperuricemia is not only a cause of gout but a contributor to the development cardiovascular diseases (CVD), diabetes and chronic kidney disease ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Association Between Serum Uric Acid Levels and Traditional Cardiovascular Risk Factors in Xiamen Residents of China: A Real-World Study

Zhang

Chen

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundSerum uric acid (SUA) levels was associated with cardiovascular diseases and cardiovascular events. However, the relationship between SUA levels and traditional cardiovascular risk factors has not been well-established among Xiamen residents. Our study aimed to estimate the relationship between SUA levels and cardiovascular risk factors among Xiamen residents using real-world data.MethodsParticipants were enrolled from eight community health service centers in Xiamen, China. Participants were divided into four groups according to quartiles of the SUA levels. The history of diseases, the use of medications and the levels of laboratory parameters were collected. The China-PAR equation was used to evaluate the 10-year atherosclerotic cardiovascular disease (ASCVD) risk.ResultsA total of 1,322 participants were enrolled. About 568 (43.0%) were men and 754 (57.0%) were women. The prevalences of hypertension, elderly, current smokers, and obesity were higher in the quartile 4 (Q4) group than the quartile 1 (Q1) group (all p < 0.001). Multivariable logistic regression analysis showed the OR for hypertension was 2.671 (95% CI 1.777–4.015, p < 0.001) in the Q4 group compared with that in the Q1 group. Further logistic regression showed the OR for hypertension was 3.254 (95% CI 1.756–6.031, p < 0.001) in men and 2.314 (95% CI 1.354–3.955, p = 0.002) in women in the Q4 group compared with that in the Q1 group, respectively. In addition, the percentage of participants with low 10-year ASCVD risk calculated by China-PAR was higher in the Q1 group than that in the Q4 group (55.86 vs. 31.82%, p < 0.001). The percentage of participants with high 10-year ASCVD risk was lower in the Q1 group compared with the Q4 group (15.32 vs. 25.45%, p < 0.001). Multiple linear logistic regression showed the 10-year China-PAR ASCVD risk scores was positively correlated with SUA after adjusting for various factors (β = 0.135, p = 0.001).ConclusionSerum uric acid was associated with several cardiovascular risk factors in Xiamen residents. The percentage of high 10-year ASDVD risk was higher in participants with hyperuricemia. Participants with hyperuricemia may experience cardiovascular benefit from uric acid-lowering therapy.

show abstract

Associations between obesity parameters and hyperuricemia by sex, age, and diabetes mellitus: A nationwide study in Korea

Bae,

Park,

Son

et al. 2023

Obesity Research & Clinical Practice

View full text Add to dashboard Cite

Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights

Cited by 7 publications

References 87 publications

The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure

The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure

Association Between Serum Uric Acid Levels and Traditional Cardiovascular Risk Factors in Xiamen Residents of China: A Real-World Study

Associations between obesity parameters and hyperuricemia by sex, age, and diabetes mellitus: A nationwide study in Korea

Contact Info

Product

Resources

About